These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10356811)

  • 1. Updated data on amprenavir.
    AIDS Patient Care STDS; 1999 May; 13(5):307. PubMed ID: 10356811
    [No Abstract]   [Full Text] [Related]  

  • 2. Trials for protease failure.
    Posit Aware; 1998; 9(5):16-7. PubMed ID: 11365884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amprenavir study results released.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
    [No Abstract]   [Full Text] [Related]  

  • 4. Amprenavir (Agenerase) now available in expanded access.
    AIDS Treat News; 1998 Oct; (No 304):5. PubMed ID: 11365864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amprenavir: a new HIV protease inhibitor.
    Med Lett Drugs Ther; 1999 Jul; 41(1057):64-6. PubMed ID: 10436772
    [No Abstract]   [Full Text] [Related]  

  • 6. Amping amprenavir with ritonavir.
    TreatmentUpdate; 2001; 12(12):10. PubMed ID: 11570075
    [No Abstract]   [Full Text] [Related]  

  • 7. Double protease inhibitor regimens with amprenavir show promise.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
    Eron JJ; Smeaton LM; Fiscus SA; Gulick RM; Currier JS; Lennox JL; D'Aquila RT; Rogers MD; Tung R; Murphy RL
    J Infect Dis; 2000 May; 181(5):1622-8. PubMed ID: 10783117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term virus suppression. Expanding therapy options with protease inhibitor].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():68-9. PubMed ID: 16385882
    [No Abstract]   [Full Text] [Related]  

  • 10. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
    [No Abstract]   [Full Text] [Related]  

  • 11. Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
    Zachary KC; Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Dec; 33(12):2075-7. PubMed ID: 11700580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M.
    Murphy MD; Marousek GI; Chou S
    J Clin Virol; 2004 May; 30(1):62-7. PubMed ID: 15072756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New treatment options.
    Fornataro K; Jefferys R
    Body Posit; 1999 Jun; 12(6):11-2. PubMed ID: 11367013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amprenavir (Agenerase).
    Res Initiat Treat Action; 2000 Mar; 6(1):32-3. PubMed ID: 11708186
    [No Abstract]   [Full Text] [Related]  

  • 15. Experimental drug available.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amprenavir, new protease inhibitor, approved.
    James JS
    AIDS Treat News; 1999 May; (No 318):1-3. PubMed ID: 11366454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients sought for ACTU studies that will help answer questions about drugs.
    Fac Notes (New Orleans La); 1998; 10(6):6. PubMed ID: 11366145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coming therapies: amprenavir.
    Gatell J
    Int J Clin Pract Suppl; 1999 Jun; 103():42-4. PubMed ID: 10622044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
    MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.